Sinopharm Modern (600420.SH)'s controlled subsidiary Sinopharm ChuanKang passed the drug GMP compliance inspection.

Zhitong Finance APP news, Sinopharm Modern (600420.SH) issued an announcement. Recently, the company's controlling subsidiary Sinopharm Group Chuankang Pharmaceutical Co., Ltd. (referred to as Sinopharm Chuankang) received the "Drug GMP Compliance Inspection Notification Letter" issued by the Sichuan Provincial Medical Products Administration. The workshop and production line involved in this GMP compliance inspection, Jinghongbao 2 (API (Tacrolimus) production line), was newly put into use after production line renovation. The product currently produced is API (Tacrolimus), with a designed capacity of 100kg/year.